DNA logo
Ginkgo Bioworks Holdings
NYSE:DNA
Published 13 Mar 2026
DNA: Future Returns Will Hinge On Monetizing Autonomous Labs By 2026
Analysts have trimmed their average price target for Ginkgo Bioworks Holdings, with cuts from $14 to $12 and from $9 to $5, reflecting reduced revenue growth assumptions, a slightly lower fair value estimate, and a higher discount rate as they wait for clearer progress on monetizing autonomous labs after the biosecurity divestiture. Analyst Commentary Bullish Takeaways Bullish analysts still see enough long term potential to maintain positive ratings, even as they trim price targets to US$12 from US$14.
AnalystConsensusTarget's avatar
AnalystConsensusTarget
Based on Analyst Price Targets
Fair Value
US$8.67
Fair Value decreased 13%
Last price US$6.49 | 25.1% undervalued
Based on -3.48% p.a. revenue growth for 3 years
Market Data 
Markets 
AI
